Integer (NYSE:ITGR) Upgraded to “Strong-Buy” at Freedom Capital

Integer (NYSE:ITGR) was upgraded by stock analysts at Freedom Capital to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

Other research analysts have also issued reports about the company. Piper Sandler restated an “overweight” rating and issued a $97.00 target price (up from $87.00) on shares of Integer in a research note on Friday, May 1st. KeyCorp reiterated an “overweight” rating and set a $104.00 price target on shares of Integer in a research note on Tuesday. Citigroup boosted their price target on shares of Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Zacks Research upgraded shares of Integer from a “strong sell” rating to a “hold” rating in a research note on Monday. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Integer in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $97.00.

Integer Trading Up 0.2%

Shares of ITGR opened at $96.46 on Wednesday. The stock’s 50-day moving average price is $92.11 and its 200 day moving average price is $87.94. The company has a quick ratio of 2.38, a current ratio of 3.75 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of 24.05, a P/E/G ratio of 2.30 and a beta of 0.64. Integer has a 12-month low of $62.00 and a 12-month high of $116.31.

Integer (NYSE:ITGR) last announced its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $1.20 EPS for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). Integer had a return on equity of 12.83% and a net margin of 7.64%.The firm had revenue of $439.58 million during the quarter, compared to the consensus estimate of $426.48 million. During the same quarter in the prior year, the business posted $1.31 EPS. Integer’s revenue was up .5% compared to the same quarter last year. Integer has set its FY 2026 guidance at 5.830-6.400 EPS. As a group, research analysts predict that Integer will post 6.04 earnings per share for the current year.

Institutional Trading of Integer

Several institutional investors have recently bought and sold shares of ITGR. Salomon & Ludwin LLC grew its position in Integer by 46.8% in the fourth quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 118 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in shares of Integer by 48.1% during the first quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 117 shares during the period. TD Private Client Wealth LLC boosted its stake in shares of Integer by 1,037.5% in the 4th quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 415 shares in the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Integer by 135.5% in the 4th quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 267 shares in the last quarter. Finally, Arax Advisory Partners grew its holdings in shares of Integer by 2,489.5% in the 4th quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 473 shares during the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.